Innocens, a spin-off company from the University Hospital Antwerp/University Antwerp, has successfully secured $1,741,706 in its latest funding round. Established in 2021, the digital health firm focuses on enhancing patient care by equipping healthcare professionals with advanced, explainable insights derived from clinical data. This capital infusion marks a significant milestone for Innocens as it progresses in its mission to improve decision-making processes in intensive care environments.
The company has developed an AI-based Clinical Decision Support System specifically designed for Neonatal Intensive Care. This innovative system aims to keep healthcare workers firmly in control of their decisions, providing 24/7 risk prediction alongside clear explanations for its reasoning. Innocens emphasizes its technology's privacy compliance and its scalability, allowing for adaptation to various intensive care settings beyond neonatology. The system is engineered to improve clinical insights and enrich data, fostering a continuously improving care environment for vulnerable patients.
This newly raised capital will be instrumental in accelerating Innocens’ growth and product development initiatives. The company plans to allocate the funds towards enhancing its AI platform, expanding its dedicated team of experts, and strategically scaling its presence within critical care units. This investment underscores confidence in Innocens' technology and its potential to deliver tangible improvements in healthcare outcomes.
Looking ahead, Innocens remains committed to its core vision: aiding the decision-making of healthcare workers who care for vulnerable infants. The company aims to continue creating value by delivering advanced tools that support clinical professionals in their vital work, ultimately contributing to better patient care and more efficient healthcare operations.
